Nicox SA (ALCOX) Price & Analysis

Compare

8 Followers

ALCOX Stock Chart & Stats

€0.41

>-€0.01(-1.83%)

At close: Jan 08 4:00 PM EST

€0.41

>-€0.01(-1.83%)

Day’s Range― - ―

52-Week Range€0.20 - €0.65

Previous CloseN/A

Volume114.32K

Average Volume (3M)588.51K

Market Cap

€36.00M

Enterprise Value€36.66M

Total Cash (Recent Filing)€11.26M

Total Debt (Recent Filing)€25.79M

Price to Earnings (P/E)―

Beta1.51

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding88,441,770

10 Day Avg. Volume452,436

30 Day Avg. Volume588,508

Financial Highlights & Ratios

PEG Ratio0.04

Price to Book (P/B)4.11

Price to Sales (P/S)1.78

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€1.50

Price Target Upside265.85% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical EfficacyNCX 470 met its primary endpoint in a second large Phase 3 glaucoma trial and showed faster onset with stronger pressure-lowering effect versus standard treatments, supporting regulatory approval prospects and potential market adoption.

Partner Financing And Commercial UpsidePartner Kowa is financing late-stage development and leading regulatory efforts while triggering milestone payments and potential royalties, which reduces the company’s development funding burden and creates future revenue upside.

Regulatory FeedbackFDA provided positive written feedback on the planned New Drug Application for NCX 470, indicating the current data package and submission format are generally acceptable and that only limited additional pharmacokinetic data is needed, lowering the risk of filing delays.

Bears Say

Market Competition And UptakeHigh competition in the glaucoma treatment market could limit NCX 470’s commercial uptake even if approved, constraining sales and market share expectations.

Regulatory Approval RiskRegulatory approval is not guaranteed and failure to obtain FDA clearance would remove the primary route to commercialization and significantly impact expected future value.

Shareholder Dilution RiskAdditional funding needs or missed milestones could force new equity issuance, creating potential dilution pressure for existing shareholders.

Nicox SA News

Nicox: Strengthened Balance Sheet and De-Risked NCX 470 Pivotal Data Support Reiterated Buy Rating

Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Nicox SA. The associated price target...

2M ago

Positive Outlook for Nicox SA: Strong Progress with NCX 470 and Substantial Upside Potential

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Nicox SA, with...

3M ago

Nicox SA: Strong Financials and Promising Pipeline Justify Buy Rating

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Nicox SA, with...

5M ago

Nicox SA’s NCX 470 Advances with Positive Phase 3 Results and Strategic Partnerships, Reinforcing Buy Rating

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Nicox SA, retaining the price target of...

6M ago

Positive Outlook for Nicox SA Driven by Successful NCX 470 Trial and Strategic Partnerships

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Nicox SA and increased the price target...

7M ago

Buy Rating for Nicox SA Driven by Strategic Developments and Financial Prospects

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Nicox SA, with...

8M ago

Nicox SA’s Strategic Developments and Promising Trials Justify Buy Rating

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Nicox SA, retaining the price target of...

8M ago

Nicox SA’s Strategic Advancements and Clinical Progress Bolster Buy Rating

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Nicox SA (0RCQ – Research Report) today and...

10M ago

Nicox SA: Promising Financial Stability and Clinical Advancements Drive Buy Rating

Nicox SA (0RCQ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today....

1y ago

Nicox Completes U.S. Patient Recruitment for NCX 470 Trial

Nicox SA (FR:ALCOX) has released an update. Nicox SA has announced the completion of patient recruitment in the...

2y ago

ALCOX FAQ

What was Nicox SA’s price range in the past 12 months?

Nicox SA lowest stock price was €0.20 and its highest was €0.65 in the past 12 months.

What is Nicox SA’s market cap?

Nicox SA’s market cap is €36.00M.

When is Nicox SA’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Nicox SA’s earnings last quarter?

Currently, no data Available

Is Nicox SA overvalued?

According to Wall Street analysts Nicox SA’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Nicox SA pay dividends?

Nicox SA does not currently pay dividends.

What is Nicox SA’s EPS estimate?

Nicox SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Nicox SA have?

Nicox SA has 88,441,770 shares outstanding.

What happened to Nicox SA’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Nicox SA?

Currently, no hedge funds are holding shares in FR:ALCOX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Nicox SA

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. The company is also developing NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, which is in preclinical evaluation. It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was incorporated in 1996 and is headquartered in Valbonne, France.

Nicox SA (ALCOX) Earnings & Revenues

Historic Earnings Reports

ALCOX Stock 12 Month Forecast

Average Price Target

€1.50

▲(265.85% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","-1":"-€1","-0.25":"-€0.25","0.5":"€0.5","1.25":"€1.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€1.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€1.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€1.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.25,0.5,1.25,2],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.479,0.5575384615384615,0.636076923076923,0.7146153846153845,0.7931538461538461,0.8716923076923077,0.9502307692307692,1.0287692307692307,1.107307692307692,1.1858461538461538,1.2643846153846154,1.3429230769230767,1.4214615384615383,{"y":1.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.479,0.5575384615384615,0.636076923076923,0.7146153846153845,0.7931538461538461,0.8716923076923077,0.9502307692307692,1.0287692307692307,1.107307692307692,1.1858461538461538,1.2643846153846154,1.3429230769230767,1.4214615384615383,{"y":1.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.479,0.5575384615384615,0.636076923076923,0.7146153846153845,0.7931538461538461,0.8716923076923077,0.9502307692307692,1.0287692307692307,1.107307692307692,1.1858461538461538,1.2643846153846154,1.3429230769230767,1.4214615384615383,{"y":1.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.306,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.25,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.23,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.226,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.233,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.328,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.342,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.377,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.344,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.3,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.298,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.37,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.479,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >